---
figid: PMC8574228__nihms-1750505-f0001
figtitle: Signalling pathways in cardiac hypertrophy
organisms:
- NA
organisms_ner:
- Drosophila melanogaster
- Homo sapiens
pmcid: PMC8574228
filename: nihms-1750505-f0001.jpg
figlink: /pmc/articles/PMC8574228/figure/F1/
number: F1
caption: Ventricular hypertrophy in heart failure with preserved ejection fraction,
  particularly in association with hypertension and neurohormonal stress, can involve
  many pathways identified in other hypertrophic syndromes. The figure shows the major
  pathways in cardiomyocytes that are thought to stimulate pathological muscle growth
  of the heart. The hormones angiotensin II (AngII), endothelin 1 (ET-1) and catecholamines
  bind to their cognate receptors, which are coupled to heterotrimeric G proteins
  to activate downstream signalling, such as the phospholipase C (PLC)–protein kinase
  C (PKC) axis. Activated PKC inhibits the insulin receptor substrate 1 (IRS1)–RACα
  serine/threonine-protein kinase (AKT)–forkhead box protein (FOXO) signalling pathway.
  β1-Adrenergic receptor (AR) stimulated protein kinase A (PKA) raises cytosolic Ca2+
  levels by phosphorylation of Ca2+-handling proteins. Transient receptor potential
  channel 1 (TRPC1), TRPC3 and TRPC6 have been linked to pathological hypertrophy
  through elevated NFAT signalling. TRPC1 and TRPC6 are also mechanosensitive. Integrin
  transmembrane receptors also transduce intracellular hypertrophic signalling by
  activating downstream effectors such as Rho. Transforming growth factor-β (TGFβ)
  signalling and receptors transmitting signals through Gq-protein-coupled receptors
  promote activation of Rho-associated protein kinase (ROCK), extracellular-signal-regulated
  kinase (ERK) and p38 mitogen-activated protein kinase (MAPK), which contributes
  to pathological cardiac hypertrophy and fibrosis. Growth factor-mediated stimulation
  of mechanistic target of rapamycin (mTOR) signalling is linked to induction of protein
  synthesis and inhibition of autophagy. Hypertrophy is also associated with depressed
  cGMP–protein kinase G (PKG) signalling (both nitric oxide (NO)-mediated and natriuretic-peptide-mediated)
  and increased phosphodiesterase type 5A (PDE5A) and PDE9A expression. Many of these
  kinases can affect sarcomeric proteins, altering myofilament Ca2+ sensitivity and
  passive stiffness. Cytokines augment cardiac hypertrophy through their receptors
  (such as the IL-6 receptor). 4EBP1, eukaryotic translation initiation factor 4E-binding
  protein 1; AC, adenylyl cyclase; ANP, atrial natriuretic peptide; AT1R, angiotensin
  II receptor type 1; ATF2, cAMP-dependent transcription factor ATF2; BNP, B-type
  natriuretic peptide; CAMKII, Ca2+/calmodulin-dependent protein kinase II; CAV1,
  caveolin 1; CBP, CREB-binding protein; CNP, C-type natriuretic peptide; cTnI, cardiac
  troponin I; DAG, diacylglycerol; eIF4E, eukaryotic translation initiation factor
  4E; ER, oestrogen receptor; FOS, proto-oncogene c-Fos; GATA4, transcription factor
  GATA4; HDAC, histone deacetylase; IP3, inositol trisphosphate; JAK, Janus kinase;
  JNK, JUN N-terminal kinase; JUN, proto-oncogene c-Jun; KATP, ATP-dependent K+ channel;
  LTCC, L-type Ca2+ channel; MAPKKK, mitogen-activated protein kinase kinase kinase;
  MEF2, myocyte enhancer factor 2; MEK, MAPK/ERK kinase; MLCK, myosin light chain
  kinase; MYBPC, cardiac myosin-binding protein C; NFAT, nuclear factor of activated
  T cells; NF-κB, nuclear factor-κB; NOS3, endothelial nitric oxide synthase; NPR-A,
  natriuretic peptide receptor A; NPR-B, natriuretic peptide receptor B; P, phosphate;
  p300, histone acetyltransferase p300; PDK1, 3-phosphoinositide-dependent protein
  kinase 1; PI3K, phosphoinositide 3-kinase; PKD, protein kinase D; PLN, cardiac phospholamban;
  pS6, ribosomal protein S6 kinase; RAF, RAF proto-oncogene serine/threonine-protein
  kinase; RGS2, regulator of G-protein signalling 2; RGS4, regulator of G-protein
  signalling 4; ROS, reactive oxygen species; RYR2, ryanodine receptor 2; S6K1, ribosomal
  protein S6 kinase-β1; S6K2, ribosomal protein S6 kinase-β2; SERCA2A, sarcoplasmic/endoplasmic
  reticulum Ca2+ ATPase; sGC, soluble guanylyl cyclase; SIRT3, mitochondrial NAD-dependent
  protein deacetylase sirtuin 3; SR, sarcoplasmic reticulum; SRC, proto-oncogene tyrosine-protein
  kinase SRC; SRF, serum response factor; STAT, signal transducer and activator of
  transcription; TGFBR, transforming growth factor-β receptor.
papertitle: Cellular and molecular pathobiology of heart failure with preserved ejection
  fraction.
reftext: Sumita Mishra, et al. Nat Rev Cardiol. ;18(6):400-423.
year: '2021'
doi: 10.1038/s41569-020-00480-6
journal_title: Nature reviews. Cardiology
journal_nlm_ta: Nat Rev Cardiol
publisher_name: ''
keywords: ''
automl_pathway: 0.8296248
figid_alias: PMC8574228__F1
figtype: Figure
redirect_from: /figures/PMC8574228__F1
ndex: ''
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC8574228__nihms-1750505-f0001.html
  '@type': Dataset
  description: Ventricular hypertrophy in heart failure with preserved ejection fraction,
    particularly in association with hypertension and neurohormonal stress, can involve
    many pathways identified in other hypertrophic syndromes. The figure shows the
    major pathways in cardiomyocytes that are thought to stimulate pathological muscle
    growth of the heart. The hormones angiotensin II (AngII), endothelin 1 (ET-1)
    and catecholamines bind to their cognate receptors, which are coupled to heterotrimeric
    G proteins to activate downstream signalling, such as the phospholipase C (PLC)–protein
    kinase C (PKC) axis. Activated PKC inhibits the insulin receptor substrate 1 (IRS1)–RACα
    serine/threonine-protein kinase (AKT)–forkhead box protein (FOXO) signalling pathway.
    β1-Adrenergic receptor (AR) stimulated protein kinase A (PKA) raises cytosolic
    Ca2+ levels by phosphorylation of Ca2+-handling proteins. Transient receptor potential
    channel 1 (TRPC1), TRPC3 and TRPC6 have been linked to pathological hypertrophy
    through elevated NFAT signalling. TRPC1 and TRPC6 are also mechanosensitive. Integrin
    transmembrane receptors also transduce intracellular hypertrophic signalling by
    activating downstream effectors such as Rho. Transforming growth factor-β (TGFβ)
    signalling and receptors transmitting signals through Gq-protein-coupled receptors
    promote activation of Rho-associated protein kinase (ROCK), extracellular-signal-regulated
    kinase (ERK) and p38 mitogen-activated protein kinase (MAPK), which contributes
    to pathological cardiac hypertrophy and fibrosis. Growth factor-mediated stimulation
    of mechanistic target of rapamycin (mTOR) signalling is linked to induction of
    protein synthesis and inhibition of autophagy. Hypertrophy is also associated
    with depressed cGMP–protein kinase G (PKG) signalling (both nitric oxide (NO)-mediated
    and natriuretic-peptide-mediated) and increased phosphodiesterase type 5A (PDE5A)
    and PDE9A expression. Many of these kinases can affect sarcomeric proteins, altering
    myofilament Ca2+ sensitivity and passive stiffness. Cytokines augment cardiac
    hypertrophy through their receptors (such as the IL-6 receptor). 4EBP1, eukaryotic
    translation initiation factor 4E-binding protein 1; AC, adenylyl cyclase; ANP,
    atrial natriuretic peptide; AT1R, angiotensin II receptor type 1; ATF2, cAMP-dependent
    transcription factor ATF2; BNP, B-type natriuretic peptide; CAMKII, Ca2+/calmodulin-dependent
    protein kinase II; CAV1, caveolin 1; CBP, CREB-binding protein; CNP, C-type natriuretic
    peptide; cTnI, cardiac troponin I; DAG, diacylglycerol; eIF4E, eukaryotic translation
    initiation factor 4E; ER, oestrogen receptor; FOS, proto-oncogene c-Fos; GATA4,
    transcription factor GATA4; HDAC, histone deacetylase; IP3, inositol trisphosphate;
    JAK, Janus kinase; JNK, JUN N-terminal kinase; JUN, proto-oncogene c-Jun; KATP,
    ATP-dependent K+ channel; LTCC, L-type Ca2+ channel; MAPKKK, mitogen-activated
    protein kinase kinase kinase; MEF2, myocyte enhancer factor 2; MEK, MAPK/ERK kinase;
    MLCK, myosin light chain kinase; MYBPC, cardiac myosin-binding protein C; NFAT,
    nuclear factor of activated T cells; NF-κB, nuclear factor-κB; NOS3, endothelial
    nitric oxide synthase; NPR-A, natriuretic peptide receptor A; NPR-B, natriuretic
    peptide receptor B; P, phosphate; p300, histone acetyltransferase p300; PDK1,
    3-phosphoinositide-dependent protein kinase 1; PI3K, phosphoinositide 3-kinase;
    PKD, protein kinase D; PLN, cardiac phospholamban; pS6, ribosomal protein S6 kinase;
    RAF, RAF proto-oncogene serine/threonine-protein kinase; RGS2, regulator of G-protein
    signalling 2; RGS4, regulator of G-protein signalling 4; ROS, reactive oxygen
    species; RYR2, ryanodine receptor 2; S6K1, ribosomal protein S6 kinase-β1; S6K2,
    ribosomal protein S6 kinase-β2; SERCA2A, sarcoplasmic/endoplasmic reticulum Ca2+
    ATPase; sGC, soluble guanylyl cyclase; SIRT3, mitochondrial NAD-dependent protein
    deacetylase sirtuin 3; SR, sarcoplasmic reticulum; SRC, proto-oncogene tyrosine-protein
    kinase SRC; SRF, serum response factor; STAT, signal transducer and activator
    of transcription; TGFBR, transforming growth factor-β receptor.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - hop
  - bsk
  - Stat92E
  - Pka-C1
  - Pka-R2
  - Pka-C3
  - Pka-R1
  - Pka-C2
  - ca
  - SERCA
  - Pkg21D
  - for
  - HDAC6
  - CaMKII
  - Mef2
  - inaC
  - Pkc98E
  - aPKC
  - Pkc53E
  - PKD
  - RyR
  - NFAT
  - sgg
  - norpA
  - sl
  - Plc21C
  - Pi3K21B
  - Pi3K59F
  - Pi3K68D
  - Pi3K92E
  - Akt
  - foxo
  - cal
  - Cam
  - lic
  - Dif
  - dl
  - Rel
  - dpp
  - gbb
  - put
  - mav
  - ras
  - Ras64B
  - Ras85D
  - Raf
  - p38b
  - Nurf-38
  - Ebp
  - AIMP2
  - p38a
  - Hrb87F
  - p38c
  - Dsor1
  - Erk7
  - rl
  - ar
  - wnd
  - Src64B
  - rho
  - Bx
  - Rho1
  - Lcp65Ab1
  - GatA
  - srp
  - pnr
  - MKP-4
  - Rok
  - Strn-Mlck
  - Nos
  - nos
  - Anp
  - tRNA:Ala-TGC-1-1
  - tRNA:Ala-TGC-2-1
  - eIF4E1
  - eIF4E7
  - eIF4E4
  - eIF4E5
  - eIF4E3
  - eIF4E6
  - eIF4EHP
  - Pdk1
  - Thor
  - S6k
  - Mtor
  - Tor
  - Nap1
  - Rpt2
  - scb
  - bt
  - sls
  - JAK1
  - JAK2
  - JAK3
  - TYK2
  - SOAT1
  - STAT1
  - STAT2
  - STAT3
  - STAT4
  - STAT6
  - STAT5A
  - STAT5B
  - PRKAR1A
  - PRKAR1B
  - PRKAR2A
  - PRKAR2B
  - PRKACA
  - PRKACB
  - PRKACG
  - ATP2A1
  - ATP2A2
  - ATP2A3
  - PRKG1
  - PLN
  - HDAC4
  - HDAC5
  - HDAC7
  - HDAC9
  - HDAC10
  - CAMK2G
  - MEF2A
  - MYEF2
  - MEF2C
  - MEF2D
  - MEF2B
  - PRRT2
  - PRKCA
  - PRKCB
  - PRKCD
  - PRKCE
  - PRKCG
  - PRKCH
  - PRKCI
  - PRKCQ
  - PRKCZ
  - PRKD3
  - CAMK4
  - CAMK1
  - CAMK1D
  - CAMK1G
  - CAMK2A
  - CAMK2B
  - CAMK2D
  - PRKD1
  - TRPC1
  - TRPC6
  - TRPC3
  - RYR1
  - RYR2
  - RYR3
  - NFATC1
  - NFATC2
  - NFATC3
  - NFATC4
  - NFAT5
  - GSK3A
  - GSK3B
  - HSPG2
  - PLCE1
  - PLCZ1
  - PLCB1
  - PLCB2
  - PLCB3
  - PLCB4
  - PLCD1
  - PLCD3
  - PLCD4
  - PLCG1
  - PLCG2
  - IRS1
  - PIK3CA
  - PIK3CB
  - PIK3CD
  - PIK3CG
  - PIK3R3
  - PIK3R4
  - PIK3R5
  - PIK3R6
  - PIK3R1
  - PIK3R2
  - AKT1
  - AKT2
  - AKT3
  - FOXO1
  - FOXO3
  - FOXO4
  - FOXO6
  - EDN1
  - FBLIM1
  - GOPC
  - CA1
  - MAP2K3
  - MAPK8
  - MAPK9
  - MAPK10
  - NFKB1
  - TGFB1
  - TGFB2
  - TGFB3
  - KRAS
  - HRAS
  - NRAS
  - SIRT3
  - ZHX2
  - ARAF
  - BRAF
  - RAF1
  - CRK
  - MAPK14
  - MAPK1
  - GRAP2
  - AHSA1
  - POLDIP2
  - MAPK11
  - MAPK12
  - MAPK13
  - MAP2K1
  - MAP2K2
  - EPHB2
  - MAPK3
  - AR
  - CAV1
  - SRC
  - RHO
  - RHOD
  - RHOA
  - RHOB
  - RHOC
  - QRSL1
  - GATA1
  - GATA2
  - GATA3
  - GATA4
  - GATA5
  - GATA6
  - ROCK1
  - ROCK2
  - MYLK
  - MYLK2
  - MYLK3
  - NOS1
  - NOS2
  - NOS3
  - MTG1
  - NPPA
  - NPPB
  - GCA
  - RGS2
  - RIEG2
  - RGS4
  - CNP
  - NPPC
  - NPR2
  - PDE9A
  - PHF5A
  - EIF4E
  - EIF4E2
  - EIF4E3
  - PDK1
  - PDPK1
  - EIF4EBP1
  - RPS6KB1
  - MYBPC2
  - MYBPC3
  - MTOR
  - IFIT1
  - PSMC1
  - CDKL2
  - CCDC91
  - H3P45
---
